Table 4 Cost-effectiveness analysis results over a life-time horizon
Indicator | Costs | LYs | QALYs | |||
|---|---|---|---|---|---|---|
Treatment | AZA | comparator | AZA | comparator | AZA | comparator |
AZA vs. BSC | € 107,168 | € 35,090 | 4.05 | 1.88 | 3.06 | 1.24 |
ICER |  |  | €33,111/LY gained | € 39,610/QALY gained | ||
AZA vs. LDC | € 115,537 | € 53,184 | 4.45 | 2.06 | 3.39 | 1.36 |
ICER |  |  | €25,953/LY gained | €30,531/QALY gained | ||
AZA vs. SDC | € 106,422 | € 59,725 | 3.96 | 1.49 | 2.94 | 0.98 |
ICER |  |  | €18,884/LY gained | €23,804/QALY gained | ||
AZA vs. CCR* | € 108,605 | € 43,170 | 4.11 | 1.85 | 3.11 | 1.22 |
ICER |  |  | €28,891/LY gained | €34,673/QALY gained | ||